Nationality: German | Year of birth: 1966
As President, Global Health, Lutz Hegemann is responsible for integrating global health and environmental, social and governance (ESG) matters into the core of the Novartis business.
In this role, Lutz leads two teams: the ESG Management Office, which integrates ESG activities across the company; and the Global Health organization, which focuses on transforming health in low- and middle-income countries, with flagship programs targeting malaria, leprosy, sickle cell disease and Chagas disease.
We are pursuing a co-ordinated approach to maximize our contribution to society and ensure as many patients as possible have access to our treatments, helping to build a strong foundation for the next phase of our global health and ESG journey.
In his ad interim role as Chief Strategy & Growth Officer, Lutz leads a newly created Strategy & Growth function for Novartis, spanning corporate strategy, research and development portfolio strategy and business development. This function will help drive the company’s growth strategy end-to-end and will look across internal and external opportunities to strengthen the Novartis pipeline with medicines that are both transformational and can make significant contributions to growth.
Before taking on his present role, Lutz was Group Head of Corporate Affairs and Global Health. He has held roles of increasing responsibility since joining Novartis in 2005 in the Consumer Health Division. He began his career as a public health physician and scientist.
Lutz is a Fellow of the Royal Society for Tropical Medicine & Hygiene and serves on the boards of the Novartis Foundation, the Swiss Alliance against Neglected Tropical Diseases, the Tanzania Training Centre of International Health, and PATH.